RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug

The FDA granted the approval of Revolution Medicines’ daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.